{"id":404947,"date":"2020-12-23T01:33:08","date_gmt":"2020-12-23T06:33:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=404947"},"modified":"2020-12-23T01:33:08","modified_gmt":"2020-12-23T06:33:08","slug":"evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/","title":{"rendered":"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors"},"content":{"rendered":"
\n

COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) — Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I\/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.<\/p>\n

The open label, multi-center study will assess the safety, tolerability, pharmacodynamic response and efficacy of EVX-02 with checkpoint inhibitors in patients who have had a complete resection of Stage IIIB\/IIIC\/IIID or Stage IV melanoma and are at high risk of recurrence. The study is planned to take place at five clinical centers in Australia, targeting recruitment of a total of 46 patients. Early data read out from this Phase I\/IIa is expected in H1 2021.<\/p>\n

Lars Wegner, CEO of Evaxion Biotech, said: \u201cWe are very excited to start this Phase I\/IIa study with EVX-02 further demonstrating the potential of Evaxion\u2019s integrated PIONEER\u2122\u00a0artificial intelligence platform to accelerate the discovery and development of a new generation of patient-specific cancer immunotherapies. We believe that the computational power behind the discovery of this compound shows that EVX-02 may have the potential to make a difference in malignant melanoma, which accounts for 1% of skin tumors and causes of 60% mortality due to skin cancers.\u201d<\/p>\n

EVX-02 is a personalized cancer immunotherapy designed based on the unique tumor genetic fingerprint of each individual patient and consists of patient-specific cancer neoepitopes incorporated into a DNA plasmid. The mutanome immunotherapy is devised by PIONEER, Evaxion\u2019s computational platform which has been shown to be capable of identifying cancer neoepitopes from matched tumor-normal DNA sequencing data and ranking of the neoepitopes according to their predicted capability in stimulating a T-cell response.<\/p>\n

The aim of EVX-02 is to promote T cell priming and expansion of effector cells for direct tumor killing. When administered, EVX-02 is taken up by antigen presenting cells and the neoepitopes are then expressed and displayed on the cell surface, thus triggering a neoepitope-specific immune response targeting the cancer cells.<\/p>\n

\n About Evaxion<\/strong>
\n
Evaxion Biotech A\/S is a clinical stage AI-immunology\u2122\u00a0platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I\/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus<\/em> (including Methicillin-resistant S. aureus<\/em>) induced skin and soft tissue infections.<\/p>\n\n\n\n\n\n\n\n
\n For more information<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Evaxion Biotech<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nLifeSci Advisors LLC<\/td>\n\u00a0<\/td>\n<\/tr>\n
Glenn S. Vraniak<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nMary-Ann Chang<\/td>\n\u00a0<\/td>\n<\/tr>\n
Chief Financial Officer<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\nManaging Director<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n gvr@evaxion-biotech.com<\/a>\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n mchang@lifesciadvisors.com<\/a>\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
t: +1 (513) 476-2669<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n+44 7483 284 853<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) — Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I\/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. The open label, multi-center study will assess the safety, tolerability, pharmacodynamic response and efficacy of EVX-02 with checkpoint inhibitors in patients who have had a complete resection of Stage IIIB\/IIIC\/IIID or Stage IV melanoma and are at high risk of recurrence. The study is planned to take place at five clinical centers in Australia, targeting recruitment of a total of 46 patients. Early data read out from this Phase I\/IIa is expected in H1 … <\/p>\n

Continue reading “Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-404947","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEvaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) — Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I\/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. The open label, multi-center study will assess the safety, tolerability, pharmacodynamic response and efficacy of EVX-02 with checkpoint inhibitors in patients who have had a complete resection of Stage IIIB\/IIIC\/IIID or Stage IV melanoma and are at high risk of recurrence. The study is planned to take place at five clinical centers in Australia, targeting recruitment of a total of 46 patients. Early data read out from this Phase I\/IIa is expected in H1 … Continue reading "Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-23T06:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion Biotech Doses First Patient in Phase I\\\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors\",\"datePublished\":\"2020-12-23T06:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/\"},\"wordCount\":477,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/\",\"name\":\"Evaxion Biotech Doses First Patient in Phase I\\\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==\",\"datePublished\":\"2020-12-23T06:33:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion Biotech Doses First Patient in Phase I\\\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors - Market Newsdesk","og_description":"COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) — Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I\/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. The open label, multi-center study will assess the safety, tolerability, pharmacodynamic response and efficacy of EVX-02 with checkpoint inhibitors in patients who have had a complete resection of Stage IIIB\/IIIC\/IIID or Stage IV melanoma and are at high risk of recurrence. The study is planned to take place at five clinical centers in Australia, targeting recruitment of a total of 46 patients. Early data read out from this Phase I\/IIa is expected in H1 … Continue reading \"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-23T06:33:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors","datePublished":"2020-12-23T06:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/"},"wordCount":477,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/","name":"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==","datePublished":"2020-12-23T06:33:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNjU4OCMzODkzNDQzIzUwMDA2OTA4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-doses-first-patient-in-phase-i-iia-melanoma-trial-of-cancer-vaccine-evx-02-in-combination-with-checkpoint-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion Biotech Doses First Patient in Phase I\/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=404947"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404947\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=404947"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=404947"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=404947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}